VALO HEALTH

Valo Health was created in 2019 by David Berry, a partner at Flagship Pioneering, the venture firm that is essentially a drug discovery factory (they built Moderna, Seres Therapeutics, Translate Bio, and dozens of others from scratch). Berry had spent years thinking about why drug development failed at such high rates — roughly 90% of drugs that enter clinical trials never reach patients — and concluded that the problem was not chemistry but data.

Drug candidates were being designed using cell lines and animal models that poorly predicted human biology. Valo's founding thesis was to flip this: start with comprehensive human datasets and work backwards to drug design.

They assembled a team of computational biologists, data scientists, and drug discovery experts in Boston and began building the Opal platform.

Valo operates on a platform partnership model. They license access to their Opal AI platform to pharma and biotech companies, who use it to design better drug candidates in their own disease areas.

They also run internal drug discovery programs using Opal, building their own pipeline of clinical candidates that they can advance independently or partner out. Revenue comes from upfront payments, milestone payments tied to drug program progress, and eventual royalties on approved drugs.

The bet is that their human-centric dataset — which integrates electronic health records, genomics, proteomics, and clinical trial data — gives them a systematic advantage over competitors working from purely synthetic or animal-derived biology.

Opal — their integrated AI drug discovery platform that combines multi-omic human datasets, physics-based molecular design, and machine learning to identify drug targets and design clinical candidates. Opal integrates data across multiple modalities: genomics, proteomics, metabolomics, electronic health records, and imaging data.

Their internal pipeline includes programs in cardiovascular disease, oncology, and neurological conditions. They have also developed capabilities in clinical trial design — using their human datasets to select patient populations most likely to respond to a given drug, which addresses one of the main reasons clinical trials fail.

Flagship Pioneering's network was the unfair advantage in the early years. Flagship has deep relationships with every major pharma company, which meant Valo had access to partnership conversations that would take a typical startup years to get.

The Novo Nordisk deal — announced in 2022 and valued at up to $1 billion — was the public validation that gave Valo credibility beyond the Flagship ecosystem. Their growth strategy is partnership-heavy: rather than building out a full clinical-stage drug company themselves, they are building the infrastructure that many drug companies use.

If that infrastructure becomes indispensable, the economics are enormous.

Proving that the data advantage is real. The AI drug discovery space is crowded with companies making similar claims — that their platform will produce better drug candidates faster.

The honest challenge is that the industry will not know which platforms actually work until the drugs they generate succeed or fail in clinical trials, which takes years. Valo's strongest answer to this challenge is the Flagship provenance and the Novo Nordisk endorsement, but neither of those substitutes for clinical data.

The other challenge is that pharmaceutical companies are increasingly building their own AI capabilities in-house, which could reduce their willingness to pay a platform company for access to something they eventually replicate internally.

Flagship Pioneering is the founding investor and ongoing strategic backer — Noubar Afeyan, who built Moderna, chairs the broader Flagship portfolio. The Series B in 2021 brought in additional institutional investors alongside Flagship.

Novo Nordisk's deal effectively made them a strategic commercial partner, which carries more weight than a purely financial investor because it means the platform is being tested in real drug programs at scale. Additional investors in later financing rounds have included healthcare-focused funds attracted by the Flagship pedigree and the Novo validation.